Literature DB >> 7909486

Radical operation after portal embolization for tumor of hilar bile duct.

S Kawasaki1, M Makuuchi, S Miyagawa, T Kakazu.   

Abstract

The clinical outcomes of patients with carcinoma of the proximal bile duct who underwent portal embolization of the right lobe followed by right extended lobectomy with (n = 3) and without (n = 9) pancreatoduodenectomy, are described. Preoperative embolization of the portal venous branch of the right hepatic lobe, which was performed with the intent of preventing postoperative hepatic failure, induced a significant increase in the volume of the future remnant liver (left lobe) (from 437 +/- 88 to 544 +/- 97 milliliters, p < 0.01). No patients died in the hospital after the resectional operation. One patient, who had poorly differentiated adenocarcinoma, died as a result of tumor recurrence 12 months after operation, and in another patient, distant lymph node metastases were found. The remaining ten patients are alive and well with no signs of recurrence. The three who underwent hepatopancreatoduodenectomy are leading a normal life 14, 21 and 22 months postoperatively.

Entities:  

Mesh:

Year:  1994        PMID: 7909486

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  15 in total

1.  Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization.

Authors:  D Azoulay; D Castaing; A Smail; R Adam; V Cailliez; A Laurent; A Lemoine; H Bismuth
Journal:  Ann Surg       Date:  2000-04       Impact factor: 12.969

2.  Does preoperative portal vein embolization have any impact on the outcome of right-side hepatectomy for Klatskin tumor?

Authors:  Mee Joo Kang; Jin-Young Jang; Wooil Kwon; Jae Woo Park; Ye Rim Chang; Sun-Whe Kim
Journal:  J Gastrointest Surg       Date:  2013-07-09       Impact factor: 3.452

3.  Safety and effectiveness of left hepatic trisegmentectomy for hilar cholangiocarcinoma.

Authors:  Kazuaki Shimada; Tsuyoshi Sano; Yoshihiro Sakamoto; Tomoo Kosuge
Journal:  World J Surg       Date:  2005-06       Impact factor: 3.352

Review 4.  Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection.

Authors:  T Kosuge; J Yamamoto; K Shimada; S Yamasaki; M Makuuchi
Journal:  Ann Surg       Date:  1999-11       Impact factor: 12.969

5.  Surgical treatment of hilar bile duct carcinoma: experience with 25 consecutive hepatectomies.

Authors:  Yoshifumi Kawarada; Bidhan C Das; Tatsushi Naganuma; Masami Tabata; Hiroki Taoka
Journal:  J Gastrointest Surg       Date:  2002 Jul-Aug       Impact factor: 3.452

6.  Long-term outcome of extended hemihepatectomy for hilar bile duct cancer with no mortality and high survival rate.

Authors:  Yasuji Seyama; Keiichi Kubota; Keiji Sano; Tamaki Noie; Tadatoshi Takayama; Tomoo Kosuge; Masatoshi Makuuchi
Journal:  Ann Surg       Date:  2003-07       Impact factor: 12.969

7.  Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation.

Authors:  S Iwatsuki; S Todo; J W Marsh; J R Madariaga; R G Lee; I Dvorchik; J J Fung; T E Starzl
Journal:  J Am Coll Surg       Date:  1998-10       Impact factor: 6.113

Review 8.  Current surgical treatment for bile duct cancer.

Authors:  Yasuji Seyama; Masatoshi Makuuchi
Journal:  World J Gastroenterol       Date:  2007-03-14       Impact factor: 5.742

9.  Safety and Oncological Benefit of Hepatopancreatoduodenectomy for Advanced Extrahepatic Cholangiocarcinoma with Horizontal Tumor Spread: Shinshu University Experience.

Authors:  Akira Shimizu; Hiroaki Motoyama; Koji Kubota; Tsuyoshi Notake; Kentaro Fukushima; Tomohiko Ikehara; Hikaru Hayashi; Koya Yasukawa; Akira Kobayashi; Yuji Soejima
Journal:  Ann Surg Oncol       Date:  2020-10-12       Impact factor: 5.344

10.  Preoperative Y-90 microsphere selective internal radiation treatment for tumor downsizing and future liver remnant recruitment: a novel approach to improving the safety of major hepatic resections.

Authors:  Seza A Gulec; Kenneth Pennington; Michael Hall; Yuman Fong
Journal:  World J Surg Oncol       Date:  2009-01-08       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.